Advertisement

Pharmaceutical Research

, Volume 30, Issue 12, pp 2993–3017 | Cite as

Transforming Lipid-Based Oral Drug Delivery Systems into Solid Dosage Forms: An Overview of Solid Carriers, Physicochemical Properties, and Biopharmaceutical Performance

  • Angel Tan
  • Shasha Rao
  • Clive A. PrestidgeEmail author
Expert Review

ABSTRACT

The diversity of lipid excipients available commercially has enabled versatile formulation design of lipid-based drug delivery systems for enhancing the oral absorption of poorly water-soluble drugs, such as emulsions, microemulsions, micelles, liposomes, niosomes and various self-emulsifying systems. The transformation of liquid lipid-based systems into solid dosage forms has been investigated for several decades, and has recently become a core subject of pharmaceutical research as solidification is regarded as viable means for stabilising lipid colloidal systems while eliminating stringent processing requirements associated with liquid systems. This review describes the types of pharmaceutical grade excipients (silica nanoparticle/microparticle, polysaccharide, polymer and protein-based materials) used as solid carriers and the current state of knowledge on the liquid-to-solid conversion approaches. Details are primarily focused on the solid-state physicochemical properties and redispersion capacity of various dry lipid-based formulations, and how these relate to the in vitro drug release and solubilisation, lipid carrier digestion and cell permeation performances. Numerous in vivo proof-of-concept studies are presented to highlight the viability of these dry lipid-based formulations. This review is significant in directing future research work in fostering translation of dry lipid-based formulations into clinical applications.

KEY WORDS

dry emulsions lipid-based drug delivery systems oral bioavailability poorly water-soluble drugs proliposomes silica-lipid hybrid solid carriers solid self-emulsifying systems 

References

  1. 1.
    Hauss DJ. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. New York: Informa Healthcare USA; 2007.Google Scholar
  2. 2.
    Fatouros DG, Karpf DM, Nielsen FS, Mullertz A. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag. 2007;3(4):591–604.PubMedGoogle Scholar
  3. 3.
    Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25(1):103–28.CrossRefGoogle Scholar
  4. 4.
    Kossena GA, Boyd BJ, Porter CJH, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci. 2003;92(3):634–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.PubMedCrossRefGoogle Scholar
  6. 6.
    Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):734–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000;11(Supplement 2):S93–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Williams HD, Sassene P, Kleberg K, Bakala-N’Goma J-C, Calderone M, Jannin V, et al.Towards the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci. 2012;101(9):3360–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Wasan KM. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev Ind Pharm. 2001;27(4):267–76.PubMedCrossRefGoogle Scholar
  12. 12.
    O’Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15(5):405–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60(6):625–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Chakraborty S, Shukla D, Mishra B, Singh S. Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73(1):1–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen Y, Chen J-M, Chen M, Gao S, Zhong Y-Q. Cubosomes as drug delivery system: recent advance. Acad J Sec Mil Med Univ. 2009;30(7):834–9.Google Scholar
  18. 18.
    Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res. 2010;27(8):1469–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci. 2003;19(4):273–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Jang DJ, Jeong EJ, Lee HM, Kim BC, Lim SJ, Kim CK. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci. 2006;28(5):405–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Christensen KL, Pedersen GP, Kristensen HG. Physical stability of redispersible dry emulsions containing amorphous sucrose. Eur J Pharm Biopharm. 2002;53(2):147–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Marchaud D, Hughes S. Solid dosage forms from self-emulsifying lipidic formulations. Pharm Technol Eur. 2008;20(4):46–9.Google Scholar
  23. 23.
    Cole ET, Cade D, Benameur H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev. 2008;60(6):747–56.PubMedCrossRefGoogle Scholar
  24. 24.
    Cannon JB. Oral solid dosage forms of lipid-based drug delivery systems. Am Pharm Rev. 2005;8(1):108–15.Google Scholar
  25. 25.
    Tang B, Cheng G, Gu J-C, Xu C-H. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13–14):606–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Shukla D, Chakraborty S, Singh S, Mishra B. Lipid-based oral multiparticulate formulations - advantages, technological advances and industrial applications. Expert Opin Drug Deliv. 2011;8(2):207–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Hentzschel CM, Sakmann A, Leopold CS. Suitability of various excipients as carrier and coating materials for liquisolid compacts. Drug Dev Ind Pharm. 2011;37(10):1200–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: speed it up, slow it down. Expert Opin Drug Deliv. 2011;8(2):191–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77.PubMedCrossRefGoogle Scholar
  30. 30.
    Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63(10–11):901–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Richter A, Steiger-Trippi K. Research on the spray drying of emulsified medical preparations. 1. Pharm Acta Helv. 1961;36:322–37.PubMedGoogle Scholar
  33. 33.
    Christensen KL, Pedersen GP, Kristensen HG. Preparation of redispersible dry emulsions by spray drying. Int J Pharm. 2001;212(2):187–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Hansen T, Holm P, Schultz K. Process characteristics and compaction of spray-dried emulsions containing a drug dissolved in lipid. Int J Pharm. 2004;287(1–2):55–66.PubMedCrossRefGoogle Scholar
  35. 35.
    Soottitantawat A, Takayama K, Okamura K, Muranaka D, Yoshii H, Furuta T, et al. Microencapsulation of l-menthol by spray drying and its release characteristics. Innovative Food Sci Emerging Technol. 2005;6(2):163–70.CrossRefGoogle Scholar
  36. 36.
    Ge Z, Zhang X-x, Gan L, Gan Y. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol Sin. 2008;29(8):990–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hansen T, Holm P, Rohde M, Schultz K. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int J Pharm. 2005;293(1–2):203–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Simovic S, Barnes TJ, Tan A, Prestidge CA. Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids. Nanoscale. 2012;4(4):1220–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009;134(1):62–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Tan A, Martin A, Nguyen T-H, Boyd BJ, Prestidge CA. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption. Angew Chem Int Ed Engl. 2012;51(22):5475–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey AK, et al. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm. 2009;6(3):861–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Simovic S, Hui H, Song Y, Davey AK, Rades T, Prestidge CA. An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles. J Control Release. 2010;143(3):367–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Bremmell KE, Tan A, Martin A, Prestidge CA. Tableting lipid-based formulations for oral drug delivery: a case study with silica nanoparticle-lipid-mannitol hybrid microparticles. J Pharm Sci. 2013;102(2):684–93.PubMedCrossRefGoogle Scholar
  44. 44.
    Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech. 2010;11(1):9–17.PubMedCrossRefGoogle Scholar
  45. 45.
    Soottitantawat A, Yoshii H, Furuta T, Ohkawara M, Linko P. Microencapsulation by spray drying: influence of emulsion size on the retention of volatile compounds. J Food Sci. 2003;68(7):2256–62.CrossRefGoogle Scholar
  46. 46.
    Li L, Yi T, Lam CW-K. Effects of spray-drying and choice of solid carriers on concentrations of Labrasol® and Transcutol® in solid self-microemulsifying drug delivery systems (SMEDDS). Molecules. 2013;18(1):545–60.PubMedCrossRefGoogle Scholar
  47. 47.
    Payne NI, Timmins P, Ambrose CV, Ward MD, Rigway F. Proliposomes: a novel solution to an old problem. J Pharm Sci. 1986;75(4):325–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm. 2000;206(1–2):110–22.PubMedGoogle Scholar
  49. 49.
    Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, Kandadi P, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm. 2012;80(2):347–57.PubMedCrossRefGoogle Scholar
  50. 50.
    Crowe LM, Womersley C, Crowe JH, Reid D, Appel L, Rudolph A. Prevention of fusion and leakage in freeze-dried liposomes by carbohydrates. Biochim Biophys Acta Biomembranes. 1986;861(C):131–40.Google Scholar
  51. 51.
    Hoekstra FA, Wolkers WF, Buitink J, Golovina EA, Crowe JH, Crowe LM. Membrane stabilization in the dry state. Comp Biochem Physiol A: Physiol. 1997;117(3):335–41.CrossRefGoogle Scholar
  52. 52.
    Barbé C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, et al. Silica particles: a novel drug-delivery system. Adv Mater. 2004;16(21):1959–66.CrossRefGoogle Scholar
  53. 53.
    Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev. 2012;64(15):1800–19.PubMedCrossRefGoogle Scholar
  54. 54.
    Rowe R. Handbook of pharmaceutical excipients. 7th ed. London: Pharmaceutical Press; 2006.Google Scholar
  55. 55.
    Pedersen GP, Faldt P, Bergenstahl B, Kristensen HG. Solid state characterisation of a dry emulsion: a potential drug delivery system. Int J Pharm. 1998;171(2):257–70.CrossRefGoogle Scholar
  56. 56.
    Myers SL, Shively ML. Solid-state emulsions: the effects of maltodextrin on microcrystalline aging. Pharm Res. 1993;10(9):1389–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Shah AV, Serajuddin ATM. Development of solid self-emulsifying drug delivery system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for lipids. Pharm Res. 2012;29(10):2817–32.PubMedCrossRefGoogle Scholar
  58. 58.
    Chen Y, Chen C, Zheng J, Chen Z, Shi Q, Liu H. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull. 2011;34(2):278–86.PubMedCrossRefGoogle Scholar
  59. 59.
    Lladser M, Medrano C, Arancibia A. The use of supports in the lyophilization of oil-in-water emulsions. J Pharm Pharmacol. 1968;20(6):450–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Kim DW, Kang JH, Oh DH, Yong CS, Choi H-G. Development of novel flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid carrier. J Microencapsul. 2012;29(4):323–30.PubMedCrossRefGoogle Scholar
  61. 61.
    Xia F, Jin H, Zhao Y, Guo X. Supercritical antisolvent-based technology for preparation of vitamin D3 proliposome and its characteristics. Chin J Chem Eng. 2011;19(6):1039–46.CrossRefGoogle Scholar
  62. 62.
    Hatanaka J, Shinme Y, Kuriyama K, Uchida A, Kou K, Uchida S, et al. In vitro and in vivo characterization of new formulations of st. john’s wort extract with improved pharmacokinetics and anti-nociceptive effect. Drug Metab Pharmacokinet. 2011;26(6):551–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Tan A, Davey AK, Prestidge CA. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharm Res. 2011;28(9):2273–87.PubMedCrossRefGoogle Scholar
  64. 64.
    Lim LH, Tan A, Simovic S, Prestidge CA. Silica-lipid hybrid microcapsules: influence of lipid and emulsifier type on in vitro performance. Int J Pharm. 2011;409(1–2):297–306.PubMedCrossRefGoogle Scholar
  65. 65.
    Yi T, Wan J, Xu H, Yang X. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose. Eur J Pharm Sci. 2008;34(4–5):274–80.PubMedCrossRefGoogle Scholar
  66. 66.
    Yi T, Wan J, Xu H, Yang X. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm. 2008;70(2):439–44.PubMedCrossRefGoogle Scholar
  67. 67.
    Balakrishnan P, Lee B-J, Oh DH, Kim JO, Hong MJ, Jee J-P, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539–45.PubMedCrossRefGoogle Scholar
  68. 68.
    Kang MJ, Jung SY, Song WH, Park JS, Choi S-U, Oh KT, et al. Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets. Drug Dev Ind Pharm. 2011;37(11):1298–305.PubMedCrossRefGoogle Scholar
  69. 69.
    Moraes M, Carvalho JMP, Silva CR, Cho S, Sola MR, Pinho SC. Liposomes encapsulating beta-carotene produced by the proliposomes method: characterisation and shelf life of powders and phospholipid vesicles. Int J Food Sci Technol. 2013;48(2):274–82.CrossRefGoogle Scholar
  70. 70.
    Elhissi AMA, Ahmed W, McCarthy D, Taylor KMG. A study of size, microscopic morphology, and dispersion mechanism of structures generated on hydration of proliposomes. J Dispersion Sci Technol. 2012;33(8):1121–6.CrossRefGoogle Scholar
  71. 71.
    Shah NM, Parikh J, Namdeo A, Subramanian N, Bhowmick S. Preparation, characterization and in vivo studies of proliposomes containing cyclosporine A. J Nanosci Nanotechnol. 2006;6(9–10):2967–73.PubMedCrossRefGoogle Scholar
  72. 72.
    Chu C, Tong S-S, Xu Y, Wang L, Fu M, Ge Y-R, et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin. 2011;32(7):973–80.PubMedCrossRefGoogle Scholar
  73. 73.
    Potluri P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv. 2006;13(3):227–32.PubMedCrossRefGoogle Scholar
  74. 74.
    Brocks DR, Betageri GV. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation. J Pharm Pharmacol. 2002;54(8):1049–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, et al. Preparation of powdered redispersible vitamin E acetate emulsion by spray-drying technique. Chem Pharm Bull. 1991;39(6):1528–31.CrossRefGoogle Scholar
  76. 76.
    You J, Cui F-D, Han X, Wang Y-S, Yang L, Yu Y-W, et al. Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil. Colloids Surf B Biointerfaces. 2006;48(1):35–41.PubMedCrossRefGoogle Scholar
  77. 77.
    Tan A, Prestidge C. Nanostructured silica-lipid hybrid microparticles: a supersaturating carrier for water- and lipid-resistant compounds. Chem Lett. 2012;41(10):1334–6.CrossRefGoogle Scholar
  78. 78.
    Agarwal V, Siddiqui A, Ali H, Nazzal S. Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int J Pharm. 2009;366(1–2):44–52.PubMedCrossRefGoogle Scholar
  79. 79.
    Onoue S, Uchida A, Kuriyama K, Nakamura T, Seto Y, Kato M, et al. Novel solid self-emulsifying drug delivery system of coenzyme Q-10 with improved photochemical and pharmacokinetic behaviors. Eur J Pharm Sci. 2012;46(5):492–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Ragno G, Cione E, Garofalo A, Genchi G, Ioele G, Risoli A, et al. Design and monitoring of photostability systems for amlodipine dosage forms. Int J Pharm. 2003;265(1–2):125–32.PubMedCrossRefGoogle Scholar
  81. 81.
    Van Speybroeck M, Williams HD, Nguyen T-H, Anby MU, Porter CJH, Augustijns P. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier. Mol Pharm. 2012;9(9):2750–60.PubMedCrossRefGoogle Scholar
  82. 82.
    Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm. 2010;7(2):522–32.PubMedCrossRefGoogle Scholar
  83. 83.
    Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets. Eur J Pharm Sci. 2008;35(5):457–64.PubMedCrossRefGoogle Scholar
  84. 84.
    Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res. 2006;23(9):2165–74.PubMedCrossRefGoogle Scholar
  85. 85.
    Fatouros DG, Mullertz A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin Drug Metab Toxicol. 2008;4(1):65–76.PubMedCrossRefGoogle Scholar
  86. 86.
    Zvonar A, Berginc K, Kristl A, Gasperlin M. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm. 2010;388(1–2):151–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Chen Y, Li G, Huang J-G, Wang R-H, Liu H, Tang R. Comparison of self-microemulsifying drug delivery system versus solid dispersion technology used in the improvement of dissolution rate and bioavailability of vinpocetine. Acta Pharmaceutica Sinica. 2009;44(6):658–66.PubMedGoogle Scholar
  88. 88.
    Huan D, Yi T, Liu Y, Xiao L, He J-K. Influence of silica on intestinal absorption of solid self-microemulsifying drug delivery systems. Acta Pharmaceutica Sinica. 2011;46(4):466–71.PubMedGoogle Scholar
  89. 89.
    Washington N, Washington C, Wilson CG. Physiological pharmaceutics: barriers to drug absorption. 2nd ed. London: Taylor and Francis; 2001.Google Scholar
  90. 90.
    Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res. 1994;11(8):1132–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717–33.PubMedCrossRefGoogle Scholar
  92. 92.
    Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16(10):1550–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16(12):1812–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Collnot E-M, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release. 2006;111(1–2):35–40.PubMedCrossRefGoogle Scholar
  95. 95.
    Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci. 2007;10(3):319–31.PubMedGoogle Scholar
  96. 96.
    Ingels F, Deferme S, Destexhe E, Oth M, Van Den Mooter G, Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int J Pharm. 2002;232(1–2):183–92.PubMedCrossRefGoogle Scholar
  97. 97.
    Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, et al. A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound. Biofactors. 2004;22(1–4):71–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev. 2001;50 Suppl 1:S13–31.PubMedCrossRefGoogle Scholar
  99. 99.
    Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm. 2000;211(1–2):89–92.PubMedCrossRefGoogle Scholar
  100. 100.
    Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm. 2009;380(1–2):96–104.PubMedCrossRefGoogle Scholar
  101. 101.
    Hamoudi MC, Bourasset F, Domergue-Dupont V, Gueutin C, Nicolas V, Fattal E, et al. Formulations based on alpha cyclodextrin and soybean oil: an approach to modulate the oral release of lipophilic drugs. J Control Release. 2012;161(3):861–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Wang Z, Sun J, Wang Y, Liu X, Liu Y, Fu Q, et al. Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation. Int J Pharm. 2010;383(1–2):1–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Sander C, Holm P. Porous magnesium aluminometasilicate tablets as carrier of a cyclosporine self-emulsifying formulation. AAPS PharmSciTech. 2009;10(4):1388–95.PubMedCrossRefGoogle Scholar
  104. 104.
    Hu X, Lin C, Chen D, Zhang J, Liu Z, Wu W, et al. Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation. Int J Pharm. 2012;438(1–2):123–33.PubMedCrossRefGoogle Scholar
  105. 105.
    Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc. 1994;26(5):2977–8.PubMedGoogle Scholar
  106. 106.
    Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11(2):301–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 1994;11(1):151–5.PubMedCrossRefGoogle Scholar
  108. 108.
    Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83(3):444–6.PubMedCrossRefGoogle Scholar
  109. 109.
    Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, et al. Redispersible dry emulsion system as novel oral dosage form of oily drugs: in vivo studies in beagle dogs. Chem Pharm Bull. 1991;39(12):3362–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297(2):638–45.PubMedGoogle Scholar
  111. 111.
    Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73(1):107–14.PubMedCrossRefGoogle Scholar
  112. 112.
    Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, et al. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. Mol Pharm. 2012;9(7):2063–79.CrossRefGoogle Scholar
  113. 113.
    El-Laithy HM, Shoukry O, Mahran LG. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm. 2011;77(1):43–55.PubMedCrossRefGoogle Scholar
  114. 114.
    Iosio T, Voinovich D, Grassi M, Pinto JF, Perissutti B, Zacchigna M, et al. Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption. Eur J Pharm Biopharm. 2008;69(2):686–97.PubMedCrossRefGoogle Scholar
  115. 115.
    Xu H, He L, Nie S, Guan J, Zhang X, Yang X, et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release. 2009;140(1):61–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Janga KY, Jukanti R, Sunkavalli S, Velpula A, Bandari S, Kandadi P, et al. In situ absorption and relative bioavailability studies of zaleplon loaded self-nanoemulsifying powders. J Microencapsul. 2013;30(2):161–72.PubMedCrossRefGoogle Scholar
  117. 117.
    Dixit RP, Nagarsenker MS. Dry adsorbed emulsion of simvastatin: optimization and in vivo advantage. Pharm Dev Technol. 2007;12(5):495–504.PubMedCrossRefGoogle Scholar
  118. 118.
    Iosio T, Voinovich D, Perissutti B, Serdoz F, Hasa D, Grabnar I, et al. Oral bioavailability of silymarin phytocomplex formulated as self-emulsifying pellets. Phytomedicine. 2011;18(6):505–12.PubMedCrossRefGoogle Scholar
  119. 119.
    Aburahma MH, Abdelbary GA. Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation. Int J Pharm. 2012;422(1–2):139–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Ian Wark Research InstituteUniversity of South AustraliaMawson LakesAustralia

Personalised recommendations